40335-00-0

Basic information

• Product Name: 2,4-diMethoxyquinoline
• Synonyms: 2,4-diMethoxyquinoline
• CAS NO: 40335-00-0
• Molecular Formula: C₁₁H₁₁NO₂
• Molecular Weight: 189.21054
• Mol File: 40335-00-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 272.9°C at 760 mmHg
• Flash Point: 100°C
• Appearance: /
• Density: 1.148g/cm³
• Vapor Pressure: 0.00988mmHg at 25°C
• Refractive Index: 1.589
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2,4-diMethoxyquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-diMethoxyquinoline(40335-00-0)
• EPA Substance Registry System: 2,4-diMethoxyquinoline(40335-00-0)

Safety Data

• Hazardous Substances Data: 40335-00-0(Hazardous Substances Data)

Usage

Uses

The Yu Borylation Ligand in tandem with bis(pinacolato)diboron (Aldrich 473294) under palladium catalysis can promote direct borylation of C(sp3)-H bonds. Yu and coworkers have displayed this on both alanine-derived amides and cyclopropanes with directing group assistance from the Yu-Wasa Auxiliary (Aldrich 791806).

General Description

Yu Borylation Ligand, also referred to as 2,4-dimethoxyquinoline, has been developed by Professor Jin-Quan Yu and coworkers. 2,4-dimethoxyquinoline can be prepared by reacting 2,4-dichloroquinoline with sodium methoxide.

InChI:InChI=1/C11H11NO2/c1-13-10-7-11(14-2)12-9-6-4-3-5-8(9)10/h3-7H,1-2H3

Upstream product

• 124-41-4 sodium methylate 
• 703-61-7 2,4-dichloroquinoline 
• 67-56-1 methanol 
• 70254-43-2 4-Hydroxy-2-quinolone 
• 74-88-4 methyl iodide 
• 27667-34-1 4-methoxyquinolin-2(1H)-one 

Downstream Products

• 868860-38-2 2,4-Dimethoxy-3-phenyl-quinoline 
• 484-29-7 dictamnine 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.